{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:07:15Z","timestamp":1794017235185,"version":"4.8.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105447","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:25:03Z","timestamp":1782343503000},"page":"105447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prognostic and predictive value of HRD in early triple negative breast cancer (TNBC)"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8086-7867","authenticated-orcid":false,"given":"Rocco","family":"Esposto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"De Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bonotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Bortot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Poletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cesselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Marco","family":"Minisini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.critrevonc.2026.105447_bib1","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"8014","key":"10.1016\/j.critrevonc.2026.105447_bib2","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41586-024-07384-2","article-title":"The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer","volume":"629","author":"Abraham","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s43856-025-01308-5","article-title":"Whole genome sequencing approach to assess homologous recombination deficiency in a pan-cancer cohort","volume":"6","author":"Al Assaad","year":"2026","journal-title":"Commun. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105447_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/genes15020162","article-title":"Genomic features of homologous recombination deficiency in breast cancer: impact on testing and immunotherapy","volume":"15","author":"Ali","year":"2024","journal-title":"Genes. (Basel)"},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105447_bib5","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1200\/JCO.23.02641","article-title":"Deep learning artificial intelligence predicts homologous recombination deficiency and platinum response from histologic slides","volume":"42","author":"Bergstrom","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105447_bib6","article-title":"Analysis of event-free survival (EFS) of stromal tumor infiltrating lymphocytes (STILs), PD-L1 expression, and their early dynamics in the neoTRIP trial","author":"Bianchini","year":"2025","journal-title":"Present. ASCO"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105447_bib7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105447_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12101595","article-title":"Alterations in homologous recombination-related genes and distinct platinum response in metastatic triple-negative breast cancers: a subgroup analysis of the ProfiLER-01 trial","volume":"12","author":"Bonnet","year":"2022","journal-title":"J. Pers. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105447_bib9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-014-3100-x","article-title":"Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients","volume":"147","author":"Byrski","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105447_bib10","article-title":"Real-world insights: neoadjuvant KEYNOTE-522 regimen in triple-negative breast cancer patients with germline BRCA mutations","author":"Celeste Tavares","year":"2025","journal-title":"Present. ASCO"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0006-291X(63)90024-X","article-title":"Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme","volume":"11","author":"Chambon","year":"1963","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16142-7","article-title":"Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer","volume":"11","author":"Chopra","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105447_bib13","doi-asserted-by":"crossref","unstructured":"Anon. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. doi:10.1038\/nature11412.","DOI":"10.1038\/nature11412"},{"issue":"6322","key":"10.1016\/j.critrevonc.2026.105447_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105447_bib15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105447_bib17","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1093\/bioinformatics\/btaa261","article-title":"ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing","volume":"36","author":"Eeckhoutte","year":"2020","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105447_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","article-title":"Olaparib monotherapy as primary treatment in unselected triple negative breast cancer","volume":"32","author":"Eikesdal","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","article-title":"Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)","volume":"32","author":"Fasching","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13073-025-01497-7","article-title":"Joint inference of mutational signatures from indels and single-nucleotide substitutions reveals prognostic impact of DNA repair deficiencies","volume":"17","author":"Ferrer-Torres","year":"2025","journal-title":"Genome Med."},{"key":"10.1016\/j.critrevonc.2026.105447_bib21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2020.12.007","article-title":"Germline BRCA1\/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy","volume":"145","author":"Furlanetto","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105447_bib22","article-title":"Chemokines as Predictive Biomarkers for Immune Checkpoint Inhibitor (ICI) Efficacy in Triple Negative Breast Cancer (TNBC)","author":"Gandhi","year":"2025","journal-title":"Present. ASCO"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105447_bib23","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/ijms20143390","article-title":"Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors","volume":"20","author":"Garutti","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105447_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ctrv.2016.06.004","article-title":"Do platinum salts fit all triple negative breast cancers?","volume":"48","author":"Gerratana","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105447_bib25","article-title":"OlympiA Trial: Long-Term Benefits of Olaparib Confirmed in High-Risk Subgroup of Breast Cancer","author":"Goodman","year":"2025","journal-title":"ASCO Post."},{"key":"10.1016\/j.critrevonc.2026.105447_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1405361","article-title":"Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches","volume":"14","author":"Guffanti","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105447_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-025-01669-z","article-title":"PARP inhibitors in the neoadjuvant setting; a comprehensive overview of the rationale for their use, past and ongoing clinical trials","author":"Habaka","year":"2025","journal-title":"Curr. Oncol. Rep."},{"issue":"7668","key":"10.1016\/j.critrevonc.2026.105447_bib28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature23470","article-title":"Mitotic progression following DNA damage enables pattern recognition within micronuclei","volume":"548","author":"Harding","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105447_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1608968","article-title":"Homologous recombination deficiency in breast cancer: genomic characteristics, clinical implications, and predictive value in neoadjuvant therapy","volume":"15","author":"Huang","year":"2025","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105447_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaa017","article-title":"Defining the mutation signatures of DNA polymerase \u03b8 in cancer genomes","volume":"2","author":"Hwang","year":"2020","journal-title":"NAR Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105447_bib31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","article-title":"Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms","volume":"44","author":"Jain","year":"2025","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105447_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10549-015-3435-y","article-title":"Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)","volume":"151","author":"Kaklamani","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105447_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.106836","article-title":"Homologous recombination deficiency in triple-negative breast cancer: multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response","volume":"158","author":"Kang","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.critrevonc.2026.105447_bib34","unstructured":"Kaplan D.M., Deshmukh S.K., Wu S., et al. Multiomic Profiling of LRRC15 in Triple Negative Breast Cancer (TNBC). Pembrolizumab: KEYNOTE-522 Biomarkers Analysis. Presentation at ASCO 2025."},{"key":"10.1016\/j.critrevonc.2026.105447_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1351778","article-title":"RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer","volume":"14","author":"Kim","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105447_bib36","article-title":"Effect of homologous recombination deficient (HRD) breast cancers on a distinct immune marker phenotype by comprehensive genomic and immune profiling (CGIP)","author":"Ko","year":"2023","journal-title":"Present. ASCO"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105447_bib37","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10549-023-07046-3","article-title":"Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes","volume":"202","author":"Lenz","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41698-025-00999-2","article-title":"Homologous recombination deficiency among patients with germline or somatic non-BRCA1\/2 homologous recombination repair gene variations","volume":"9","author":"Li","year":"2025","journal-title":"NPJ Precis. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105447_bib40","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1158\/2767-9764.CRC-25-0151","article-title":"Methylation-based ctDNA tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors in RADIOHEAD, a real-world pan-cancer study","volume":"5","author":"Liang","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105447_bib41","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1200\/JCO.19.01304","article-title":"Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant","volume":"38","author":"Litton","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105447_bib42","article-title":"Efficacy and safety of PARP inhibitors in advanced or metastatic triple-negative breast cancer: a systematic review and meta-analysis","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105447_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105447_bib44","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response\u2014final results from GeparSixto","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105447_bib45","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nm.3369","article-title":"Mechanisms of resistance to therapies targeting BRCA-mutant cancers","volume":"19","author":"Lord","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-cellbio-020520-120627","article-title":"Nuclear membrane rupture and its consequences","volume":"36","author":"Maciejowski","year":"2020","journal-title":"Annu. Rev. Cell. Dev. Biol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105447_bib47","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.annonc.2020.08.2064","article-title":"TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker","volume":"31","author":"Mayer","year":"2020","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105447_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS. One"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105447_bib49","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ijc.31898","article-title":"BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy","volume":"144","author":"Mio","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105447_bib50","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10549-022-06529-z","article-title":"Examining the prevalence of homologous recombination repair defects in ER+ breast cancers","volume":"192","author":"Moore","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib51","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s40001-024-01936-y","article-title":"AcornHRD: an HRD algorithm highly associated with anthracycline-based neoadjuvant chemotherapy in breast cancer in China","volume":"29","author":"Pan","year":"2024","journal-title":"Eur. J. Med. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41523-024-00653-3","article-title":"Use of ctDNA in early breast cancer: analytical validity and clinical potential","volume":"10","author":"Panet","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105447_bib53","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tranon.2019.10.010","article-title":"Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review","volume":"13","author":"Pellegrino","year":"2020","journal-title":"Transl. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105447_bib54","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1\/2 Inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105447_bib55","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"issue":"38","key":"10.1016\/j.critrevonc.2026.105447_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202309755","article-title":"Dissecting the distinct tumor microenvironments of HRD and HRP ovarian cancer: implications for targeted therapies to overcome PARPi resistance in HRD tumors and refractoriness in HRP tumors","volume":"11","author":"Qiu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.critrevonc.2026.105447_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100312","article-title":"Liquid biopsy in breast cancer: redefining precision medicine","volume":"9","author":"Schiavone","year":"2025","journal-title":"J. Liq. Biopsy"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105447_bib58","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","volume":"145","author":"Schlacher","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105447_bib59","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/annonc\/mdx821","article-title":"Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)","volume":"29","author":"Sharma","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105447_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.826577","article-title":"Immune checkpoint inhibitors in tumors harboring homologous recombination deficiency: challenges in attaining efficacy","volume":"13","author":"Silva","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41523-017-0024-8","article-title":"The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk","volume":"3","author":"Slavin","year":"2017","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105447_bib62","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s43018-022-00400-2","article-title":"Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer","volume":"3","author":"Spring","year":"2022","journal-title":"Nat. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105447_bib63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib64","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1038\/s41598-020-59671-3","article-title":"Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma","volume":"10","author":"Takaya","year":"2020","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105447_bib65","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-19-0664","article-title":"Association of tumor-infiltrating lymphocytes with homologous recombination deficiency and BRCA1\/2 status in patients with early triple-negative breast cancer: a pooled analysis","volume":"26","author":"Telli","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105447_bib66","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2014.57.0085","article-title":"Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1\/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105","volume":"33","author":"Telli","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105447_bib67","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105447_bib68","doi-asserted-by":"crossref","first-page":"7720","DOI":"10.1073\/pnas.1213431110","article-title":"Microhomology-mediated End Joining and Homologous Recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells","volume":"110","author":"Truong","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105447_bib69","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.19.03292","article-title":"TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial)","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105447_bib70","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"192","key":"10.1016\/j.critrevonc.2026.105447_bib71","doi-asserted-by":"crossref","DOI":"10.3791\/64881","article-title":"Visualizing DNA damage repair proteins in patient-derived ovarian cancer organoids via immunofluorescence assays","author":"van Biljon","year":"2023","journal-title":"J. Vis. Exp."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105447_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101660","article-title":"SOLO3 overall survival data: the final nail in the coffin for PARP inhibitor monotherapy in gBRCA-mutated, previously-treated recurrent ovarian cancer?","volume":"35","author":"Vasconcellos","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105447_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2023.103547","article-title":"Structure and mechanism in non-homologous end joining","volume":"130","author":"Vogt","year":"2023","journal-title":"DNA Repair. (Amst. )"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib74","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s44276-025-00122-9","article-title":"Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review","volume":"3","author":"Wang","year":"2025","journal-title":"BJC Rep."},{"key":"10.1016\/j.critrevonc.2026.105447_bib75","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-024-07436-1","article-title":"Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer","author":"Wang","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib76","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-025-00740-y","article-title":"Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics","volume":"13","author":"Witz","year":"2025","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105447_bib77","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s40364-025-00814-x","article-title":"The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers","volume":"13","author":"Xu","year":"2025","journal-title":"Biomark. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105447_bib78","first-page":"280","article-title":"Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors","volume":"4","author":"Zhao","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.critrevonc.2026.105447_bib79","doi-asserted-by":"crossref","unstructured":"Zhang L., Wu Z., Li J., et al. Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial. Published online 2023. doi:10.1200\/PO.22.","DOI":"10.1200\/PO.22.00337"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105447_bib80","article-title":"ChosenHRDw: a novel tool for the detection of homologous recombination deficiency (HRD) using low-pass whole-genome sequencing","volume":"40","author":"Zhang","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:40:14Z","timestamp":1793943614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":80,"alternative-id":["S1040842826003343"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105447","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic and predictive value of HRD in early triple negative breast cancer (TNBC)","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105447"}}